Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy

Introduction: Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear. Materials and methods: We studied 111 patients with APL. Arsenic tri...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 17; no. 1; pp. 131 - 134
Main Authors: Ghavamzadeh, A., Alimoghaddam, K., Ghaffari, S. H., Rostami, S., Jahani, M., Hosseini, R., Mossavi, A., Baybordi, E., Khodabadeh, A., Iravani, M., Bahar, B., Mortazavi, Y., Totonchi, M., Aghdami, N.
Format: Journal Article
Language:English
Published: Oxford Oxford University Press 01-01-2006
Oxford Publishing Limited (England)
Subjects:
Adolescent
Adult
Aged
Antineoplastic agents
Antineoplastic Agents - therapeutic use
APL
Arsenic Trioxide
Arsenicals - therapeutic use
Biological and medical sciences
Child
Disease-Free Survival
Female
Hematologic and hematopoietic diseases
Humans
Leukemia, Promyelocytic, Acute - drug therapy
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Leukocytosis
Male
Medical sciences
Middle Aged
minimal residual disease
Neoplasm Proteins - genetics
Neoplasm Proteins - metabolism
Neoplasm Recurrence, Local - drug therapy
Neoplasm, Residual - drug therapy
Oncogene Proteins, Fusion - genetics
Oncogene Proteins, Fusion - metabolism
Oxides - therapeutic use
Pharmacology. Drug treatments
Prognosis
Remission Induction
Reverse Transcriptase Polymerase Chain Reaction
Survival Rate
Treatment Outcome
Antineoplastic agent
Promyelocytic leukemia
Chemotherapy
Treatment
Acute
Retinoid
Minimal residual disease
Arsenic trioxide
Malignant hemopathy
APL
M3 acute myelocytic leukemia
Tretinoin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear. Materials and methods: We studied 111 patients with APL. Arsenic trioxide was infused at 0.15 mg/kg daily dose, until complete remission was achieved. Then, after 28 days of rest, arsenic trioxide was infused daily for 28 days as consolidation therapy. We studied minimal residual disease (MRD) by semi-sensitive reverse transcription polymerase chain reaction (RT–PCR) on peripheral blood samples. Results: Complete remission was observed in 95 patients (85.6%). With the median (range) follow-up period of 16.5 (1–57) months, 1- and 2-year disease-free survival was 88.3% and 63.7%, respectively; 24 patients relapsed, 19 of whom achieved a second complete remission, again by arsenic trioxide. Third and fourth remissions were seen in some relapsed patients, again by arsenic trioxide. For patients in complete remission, 1- and 3-year survival was 95.5% and 87.6%, respectively. MRD was positive in four (8.3%) out of 48 cases during 1 year after remission induction; three of them relapsed clinically. Conclusions: Arsenic trioxide is effective as first-line treatment for APL. Results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.
Bibliography:istex:B1A5136FF5DD5E2CB596B8869C9FC9E9EEAE5509
Correspondence to: Dr K. Alimoghaddam, Haematology, Oncology and BMT Research Centre of Tehran University of Medical Sciences, Shariati Hospital, Kargar Ave., Tehran 14114, Iran. Tel: +98-91-21711635; Fax: +98-21-88004140; E-mail: alimgh@ams.ac.ir
ark:/67375/HXZ-MBQF4RZB-L
local:mdj019
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdj019